Please enable Javascript
Zachary Bessette
Zachary Bessette
Articles by Zachary Bessette
CONTACT-02: Final OS Results of Cabo/Atezo Versus Second Novel Hormonal Therapy for mCRPC
Zachary Bessette
CRPC
|
October 1, 2024
The final results of the CONTACT-02 trial show favorable, but not statistically significant, benefit for cabo/atezo in mCRPC.
Read More
NIAGARA Offers Paradigm-Shift for Neoadjuvant Treatment of MIBC
Zachary Bessette
Muscle Invasive Urothelial Carcinoma
|
September 17, 2024
Perioperative durvalumab with NAC offers “meaningful improvement” in EFS and OS for patients with cisplatin-ineligible ...
Read More
SunRISe-1: TAR-200, Cetrelimab for BCG-Unresponsive High-Risk NMIBC
Zachary Bessette
Non-Muscle Invasive Urothelial Carcinoma
|
September 17, 2024
Results of SunRISe-1 provide support for TAR-200 monotherapy in patients with BCG-unresponsive high-risk NMIBC.
Read More
EV-302: Nectin-4 Expression and Response to First-Line EV/Pembro
Zachary Bessette
Advanced Urothelial Carcinoma
|
September 13, 2024
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
Read More
Futibatinib Plus Pembrolizumab for Patients With Metastatic Urothelial Carcinoma
Zachary Bessette
Advanced Urothelial Carcinoma
|
September 12, 2024
A phase 2 study highlights the “encouraging” antitumor activity from futibatinib plus pembrolizumab for patients with ...
Read More
Nivo, Chemoradiotherapy for Patients With nmMIBC Not Undergoing Cystectomy
Zachary Bessette
Muscle Invasive Urothelial Carcinoma
|
September 11, 2024
The addition of nivo to trimodality therapy may improve RFS in patients with non-metastatic muscle-invasive bladder cancer.
Read More
FDA Accepts New Drug Application for Prostate Cancer Imaging Agent
Zachary Bessette
Prostate Cancer Diagnostics
|
July 24, 2024
The FDA has accepted an NDA for TLX007-CDx, a cold kit for the preparation of PSMA-PET imaging for prostate cancer.
Read More
PSMA Tandem Treatment Offers Benefit for Patients With mCRPC
Zachary Bessette
RLT
|
June 11, 2024
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
Read More
18F-rhPSMA-7 Versus Conventional Salvage Radiotherapy for BCR
Zachary Bessette
Prostate Cancer Diagnostics
|
June 11, 2024
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Read More
NEPTUNES: Nivolumab, Ipilimumab for Metastatic Prostate Cancer With an Immunogenic Signature
Zachary Bessette
CRPC
|
June 4, 2024
Dr. Mark David Linch presented the results of NEPTUNES: a multicenter, 2-cohot, biomarker-selected, phase 2 trial.
Read More
CHAARTED2: Cabazitaxel Plus Abiraterone After Initial Docetaxel for mCRPC
Zachary Bessette
CRPC
|
June 3, 2024
Results from the CHAARTED2 trial was presented by Dr. Kyriakopoulos of the University of Wisconsin Carbone Cancer Center.
Read More
SURE-01/02: Perioperative Sacituzumab Govitecan for Patients With MIBC
Zachary Bessette
Muscle Invasive Urothelial Carcinoma
|
June 1, 2024
Neoadjuvant SG shows promising clinical activity in patients with MIBC and may help avoid radical cystectomy.
Read More
HERCULES: Pembrolizumab Plus Platinum-Based Chemotherapy for First-line Advanced Penile Cancer
Zachary Bessette
Testicular, Penile, and Rare Malignancies
|
May 31, 2024
A recent trial provides the first evidence of efficacy from ICIs in PSCC with a manageable safety profile.
Read More
NABUCCO Update: Efficacy, Biomarker Analysis of Preoperative Ipilimumab Plus Nivolumab
Zachary Bessette
Advanced Urothelial Carcinoma
|
May 31, 2024
An update on clinical efficacy and an exploratory biomarker analysis from the NABUCCO trial for patients with stage III UC.
Read More
First-line RCC Systemic Therapy Following Adjuvant Immunotherapy
Zachary Bessette
Advanced Renal Cell Carcinoma
|
June 10, 2024
Patients with RCC who experience disease recurrence after adjuvant IO benefit from subsequent systemic therapies.
Read More
High-Dose Chemotherapy Outcomes in Men With Germ Cell Cancer
Zachary Bessette
Testicular, Penile, and Rare Malignancies
|
May 31, 2024
The SWENOTECA cancer care program sought to evaluate survival, toxicity in patients treated with HDCT from 2011 through 2021.
Read More
EMBARK: Post Hoc Analysis of Impact of Treatment Suspension on HRQOL
Zachary Bessette
Localized
|
May 31, 2024
Researchers attempted to confirm whether treatment suspension for EMBARK patients may lead to improvements in HRQOL.
Read More
Analysis of the Cisplatin-Ineligible Population in EV-302
Zachary Bessette
Advanced Urothelial Carcinoma
|
May 30, 2024
Dr. van der Heijden presents a follow-up analysis of patients who were cisplatin-ineligible at randomization for EV-302.
Read More
KEYNOTE-361: Quantitative ctDNA Analysis in Patients With Advanced UC
Zachary Bessette
Advanced Urothelial Carcinoma
|
May 29, 2024
A retrospective analysis of ctDNA data by clinical outcomes with pembro vs chemotherapy for aUC from KEYNOTE-361.
Read More
Doublet Therapy Versus Monotherapy for Patients With Metastatic Chromophobe RCC
Zachary Bessette
nccRCC
|
June 7, 2024
Dr. Doshi and colleagues designed an analysis of patients with metastatic ChRCC to better understand first-line therapy.
Read More
Load More